Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: Results from the non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR), diabete de type 2, nephropathie et genetique (DIAB2NEPHROGENE), and survie, diabete de type 2 et genetique (SURDIAGENE) studies

Diabetes Care

Volumn 31, Issue 10, 2008, Pages

  Hadjadj, Samy ^a,b   Roussel, Ronan ^b,c,d   Marre, Michel ^b,c,d  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ACE GENE; DEATH; GENE; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HUMAN; INDEL MUTATION; KIDNEY FAILURE; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; PROTECTION;

EID: 64549148469     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-1229     Document Type: Letter

References (6)

1. Ng, DPK: Prognostic value of the insertion/ deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies: response to Hadjadj et al. (Letter). Diabetes Care 31:e78, 2008. DOI: 10.2337/dc08-1091
2. Ng DP, Placha G, Choo S, Chia KS, War-ram JH, Krolewski AS: A disease haplo-type for advanced nephropathy in type 2 diabetes at the ACE locus. Diabetes 55: 2660-2663, 2006
3. Hadjadj S, Fumeron F, Roussel R, Saulnier PJ, Gallois Y, Ankotche A, Tra-vert F, Khalil CA, Miot A, Alhenc-Gelas F, Lievre M, Marre M: Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies. Diabetes Care 31:1847-1852,2008
4. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney lnt 63:225-232, 2003
5. Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J, Shahinfar S, Wong PH, Lyle PA, Rossing P, Brenner BM: ACE gene polymorphism and losar-tan treatmentin type 2 diabetic patients with nephropathy. J Am Soc Nephrol 19: 771-779, 2008
6. Hadjadj S, Tarnow L, Forsblom C, Ka-zeem G, Marre M, Groop PH, Parving HH, Cambien F, Tregouet DA, Gut IG, Theva A, Gauguier D, Farrall M, Cox R, Matsuda F, Lathrop M, Hager-Vionnet N: Association between angiotensin- converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. ] Am Soc Nephrol 18:1284-1291,2007